Managing type 2 diabetes with IDegLira: A real world perspective

You will learn:
• The most effective way to prevent or reduce diabetes-related morbidity and mortality is meticulous control of glycaemia, blood pressure and dyslipidaemia, and regular examinations to facilitate timeous intervention for complications
• Type 2 diabetes is progressive and most patients will eventually need insulin to control blood glucose
• Barriers to prescribing insulin and compliance with insulin therapy include concerns over hypoglycaemia, weight gain and multiple daily injections
• IDegLira is a fixed-ratio combination of the ultralong-acting, once-daily basal insulin, degludec, and the GLP-1RA, liraglutide. It reduces both fasting and postprandial glucose with a low risk of side effects compared to insulin degludec or liraglutide monotherapies
• Compared with basal insulin and basal bolus therapy, more patients treated with IDegLira achieve glycaemic targets with no hypoglycaemia or weight gain